Patents by Inventor Francis B. Ntumngia

Francis B. Ntumngia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOF
    Publication number: 20240083956
    Abstract: Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 14, 2024
    Inventors: John H. Adams, Christopher L. King, Niraj H. Tolia, Edwin Chen, Nichole Diane Salinas, Miriam Thankam George, Francis B. Ntumngia, Samantha Jones Barnes
  • Synthetic plasmodium antigens, compositions, and uses thereof
    Patent number: 11787845
    Abstract: Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: October 17, 2023
    Assignees: UNIVERSITY OF SOUTH FLORIDA, WASHINGTON UNIVERSITY, CASE WESTERN RESERVE UNIVERSITY
    Inventors: John H. Adams, Christopher L. King, Niraj H. Tolia, Edwin Chen, Nichole Diane Salinas, Miriam Thankam George, Francis B. Ntumngia, Samantha Jones Barnes
  • Synthetic plasmodium antigens, compositions, and uses thereof
    Patent number: 10927153
    Abstract: Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: February 23, 2021
    Assignees: University of South Florida, Washington University, Case Western Reserve University
    Inventors: John H. Adams, Christopher L. King, Niraj H. Tolia, Edwin Chen, Nichole Diane Salinas, Miriam Thankam George, Francis B. Ntumngia, Samantha Jones Barnes
  • Synthetic antigen based on the ligand domain of the plasmodium vivax duffy binding protein
    Patent number: 9120869
    Abstract: The disclosure provides compositions that are useful for eliciting a strain-transcending immune response in an animal or human directed against the blood-stage of the malarial parasite Plasmodium vivax. The compositions are based on the ligand domain of Plasmodium vivax Duffy binding protein (PvDBPII). Polar charged polymorphic residues within the dominant strain-specific B-cell epitope were mutated to uncharged residues (e.g. serine, alanine and threonine). This DEKnull variant of PvDBPII produced in bacteria can be purified and refolded in vitro to mimic conformation and erythrocyte binding function of native DBPII. Immunogenicity of DEKnull was confirmed by administration to mice. Compared to the naturally-occurring, strain variant DBPII, DEKnull elicits antibodies that are more broadly reactive with different strain variants of DBPII and enhances production of functional inhibitory antibodies to the shared protective epitopes of native DBPII.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: September 1, 2015
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: John H. Adams, Francis B. Ntumngia, Jesse L. Schloegel, Samantha J. Barnes, Amy M. McHenry, Patchanee Chootong
  • Synthetic antigen based on the ligand domain of the duffy binding protein
    Patent number: 8784832
    Abstract: The disclosure provides compositions that are useful for eliciting a strain-transcending immune response in an animal or human directed against the blood-stage of the malarial parasite Plasmodium vivax. The compositions are based on the ligand domain of Plasmodium vivax Duffy binding protein (PvDBPII). Polar charged polymorphic residues within the dominant strain-specific B-cell epitope were mutated to uncharged residues (e.g. serine, alanine and threonine). This DEKnull variant of PvDBPII produced in bacteria can be purified and refolded in vitro to mimic conformation and erythrocyte binding function of native DBPII. Immunogenicity of DEKnull was confirmed by administration to mice. Compared to the naturally-occurring, strain variant DBPII, DEKnull elicits antibodies that are more broadly reactive with different strain variants of DBPII and enhances production of functional inhibitory antibodies to the shared protective epitopes of native DBPII.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: July 22, 2014
    Assignee: University of South Florida (A Florida Non-Profit Corporation)
    Inventors: John H. Adams, Francis B. Ntumngia, Jesse L. Schloegel, Samantha J. Barnes, Amy M. McHenry, Patchanee Chootong
  • Synthetic Antigen Based on the Ligand Domain of the Plasmodium vivax Duffy Binding Protein
    Publication number: 20130045225
    Abstract: The disclosure provides compositions that are useful for eliciting a strain-transcending immune response in an animal or human directed against the blood-stage of the malarial parasite Plasmodium vivax. The compositions are based on the ligand domain of Plasmodium vivax Duffy binding protein (PvDBPII). Polar charged polymorphic residues within the dominant strain-specific B-cell epitope were mutated to uncharged residues (e.g. serine, alanine and threonine). This DEKnull variant of PvDBPII produced in bacteria can be purified and refolded in vitro to mimic conformation and erythrocyte binding function of native DBPII. Immunogenicity of DEKnull was confirmed by administration to mice. Compared to the naturally-occurring, strain variant DBPII, DEKnull elicits antibodies that are more broadly reactive with different strain variants of DBPII and enhances production of functional inhibitory antibodies to the shared protective epitopes of native DBPII.
    Type: Application
    Filed: August 20, 2012
    Publication date: February 21, 2013
    Applicant: University of South Florida ( A Florida Non-Profit Corporation )
    Inventors: John H. Adams, Francis B. Ntumngia, Jesse L. Schloegel, Samantha J. Barnes, Amy M. McHenry, Patchanee Chootong